The GLP-1 "Integrated Coverage" Model
By January 2026, managing GLP-1 medications (like Wegovy and Zepbound) has become the top priority for 77% of large US employers. The focus has moved from simple "coverage" to "outcome-based" integration.
Mandatory Lifestyle Wraparounds: Employers now pair GLP-1 prescriptions with intensive coaching and nutritional support. Clinical data from early 2026 suggests this "dual-path" approach improves long-term weight maintenance and reduces the "relapse cost" when medication is tapered.
Direct-to-Employer (DTE) Models: Many firms are bypassing traditional Pharmacy Benefit Managers (PBMs) to contract directly with manufacturers or specialty clinics. This provides better price transparency and ensures that these medications are used as a preventive tool for chronic conditions like sleep apnea and heart disease.
Deprescribing Protocols: New corporate policies include "continuation criteria," requiring employees to meet specific health milestones to maintain subsidized access to high-cost medications.